2021 Volume 70 Issue 3 Pages 529-534
[Introduction] In cases of lower thoracic aortic surgery at low temperatures, hemostasis after cardiopulmonary bypass detachment is sometimes difficult to achieve owing to coagulopathy. Cryoprecipitate (Cryo) is a concentrated form of a coagulation factor containing fibrinogen (Fbg), which can be efficiently supplemented in small volumes. We started the preparation of Cryo from November 2017 and analyzed its effects on acute aortic dissection. [Materials and Methods] For 28 cases without Cryo transfusion (Non-Cryo group) and 22 cases with Cryo transfusion (Cryo group), changes in the blood products (RBC, FFP, and PC) used during and after surgery, the use of Cryo, and the Fbg concentration before and after Cryo transfusion were analyzed. [Results] During surgery, the mean RBC units transfused decreased (Non-Cryo group, 10.6 units; Cryo group, 6.9 units), and the mean FFP units transfused decreased (Non-Cryo group, 17.0 units; Cryo group, 13.4 units). After surgery, the mean RBC units transfused decreased (Non-Cryo group, 10.1 units; Cryo group, 5.7 units), and the mean FFP units transfused decreased (Non-Cryo group, 15.1 units; Cryo group, 5.7 units). After Cryo administration, the mean Fbg concentration increased significantly (before Cryo transfusion, 113 mg/dL; after Cryo transfusion, 185 mg/dL). [Discussion] Cryo can not only reduce the amount of blood components used and our workload, but also enabled the efficient replacement of Fbg. To use Cryo properly, it is important to check the Fbg concentration before transfusion and control the inventory of blood products. [Conclusion] Our current study showed that Cryo is useful for reducing the amounts of blood products used and Fbg replacement therapy.
